Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α.
Xingliang ZhouYiwei LiuYi ShenLijun ChenWenting HuYi YanBei FengLi XiangYifan ZhuChenyu JiangZihao DaiXu HuangLiwei WuTianyu LiuLijun FuCai-Wen DuanShuhong ShenJun LiHao ZhangPublished in: European heart journal (2024)
This study revealed that crosstalk between tumour cells and cardiomyocytes during chemotherapy could disturb cardiac energy metabolism and impair heart function. IL-1α neutralizing antibody treatment is a promising strategy for alleviating chemotherapy-induced cardiotoxicity in AML patients.
Keyphrases
- chemotherapy induced
- end stage renal disease
- acute myeloid leukemia
- left ventricular
- ejection fraction
- newly diagnosed
- induced apoptosis
- locally advanced
- chronic kidney disease
- heart failure
- liver failure
- oxidative stress
- prognostic factors
- bone marrow
- dendritic cells
- squamous cell carcinoma
- single cell
- patient reported outcomes
- intensive care unit
- dengue virus
- hepatitis b virus
- combination therapy